Pick Your Community: | Hopkins | Muhlenberg | Daviess | Christian | Henderson | Lakes | McCracken | Webster
Davis Motor Sales banner ad

FDA Approves New Drug for Advanced Prostate Cancer

fda2WASHINGTON, D.C. (5/15/13) - The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.

Prostate cancer forms in a gland in the male reproductive system found below the bladder and in front of the rectum. The male sex hormone testosterone stimulates the prostate tumors to grow. According to the National Cancer Institute, an estimated 238,590 men will be diagnosed with prostate cancer and 29,720 will die from the disease in 2013.

Xofigo is being approved more than three months ahead of the product’s prescription drug user fee goal date of Aug. 14, 2013, the date the agency was scheduled to complete review of the drug application. The FDA reviewed Xofigo under the agency’s priority review program, which provides for an expedited review of drugs that appear to provide safe and effective therapy when no satisfactory alternative therapy exists, or offer significant improvement compared to marketed products.

“Xofigo binds with minerals in the bone to deliver radiation directly to bone tumors, limiting the damage to the surrounding normal tissues,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Xofigo is the second prostate cancer drug approved by the FDA in the past year that demonstrates an ability to extend the survival of men with metastatic prostate cancer.”

In August 2012, the FDA approved Xtandi to treat men with metastatic castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone. Xtandi is approved for patients who have previously been treated the chemotherapy drug docetaxel.

Xofigo’s safety and effectiveness were evaluated in a single clinical trial of 809 men with symptomatic castration-resistant prostate cancer that spread to bones but not to other organs. Patients were randomly assigned to receive Xofigo or a placebo plus best standard of care.

The study was designed to measure overall survival. Results from a pre-planned interim analysis showed men receiving Xofigo lived a median of 14 months compared to a median of 11.2 months for men receiving placebo. An exploratory updated analysis conducted later in the trial confirmed Xofigo’s ability to extend overall survival.

The most common side effects reported during clinical trials in men receiving Xofigo were nausea, diarrhea, vomiting and swelling of the leg, ankle or foot. The most common abnormalities detected during blood testing included low levels of red blood cells (anemia), lymphocytes (lymphocytopenia), white blood cells (leukopenia), platelets (thrombocytopenia) and infection-fighting white blood cells (neutropenia).

Xofigo is marketed by Wayne, N.J.-based Bayer Pharmaceuticals. Xtandi is co-marketed by Astellas Pharma U.S., Inc. of Northbrook, Ill., and Medivation, Inc. of San Francisco, Calif.
 
SurfKY News
Information provided by the United States Food and Drug Administration

© Copyright 2014 SurfKY News Group, Inc. All rights reserved. This material may not be published, broadcast, or rewritten without permission. SurfKY News encourages you to share this story by using one of the social media links below.

In Other News...

Dawson Springs Police Reports Released

DAWSON SPRINGS, Ky. (9/1/14) — The Dawson Springs Police Department released the following arrest reports Monday, Sept.… Read More

WKCTC Kicks Off New Diversity and Inclusion Program Series

PADUCAH, Ky. (9/1/14) — West Kentucky Community and Technical College kicks off its new diversity and inclusion program… Read More

Most Read This Week (Site-Wide)

August 29, 2014 8205

Luke's Flea Market Vendors' Home Away…

in News by Charles W. Riley II, SurfKY News
August 30, 2014 7589

One Hospitalized After Officer-Involved…

in Top Stories by Charles W. Riley II, SurfKY News
August 28, 2014 7559

Police Pursuit Spans Parts of Northern…

in Top Stories by Alex Piper, MCSO
August 31, 2014 4839

Passenger in Officer-Involved Shooting…

in Top Stories by Rita Dukes Smith, SurfKY News Director
August 29, 2014 3946

Business Spotlight - Magical Memories…

in Top Stories by Charles W. Riley II, SurfKY News

Most Read Stories from Hopkins County

August 30, 2014 3188

Ponderosa Madisonville to Donate 10…

in Top Stories by Rita Dukes Smith, SurfKY News Director
August 30, 2014 1309

City of Madisonville Says 'Goodbye' to…

in Top Stories by Amber Averitt, SurfKY News
September 01, 2014 950

Hopkins County Misdemeanor Indictments

in Top Stories by Karen McKnight
August 29, 2014 894

MCC Announces New Board Members

in Top Stories by Joyce Riggs
August 29, 2014 579

Trover Health Endowment Reaches $100,000…

in Top Stories by Joyce Riggs

Most Read Stories from Owensboro

August 29, 2014 2574

Daviess County Sheriff’s Office Activity…

in News by Dennis Beard, SurfKY News
August 29, 2014 2489

Owensboro Police Department Activity…

in News by Dennis Beard, SurfKY News
August 28, 2014 2199

Downtown Trolley to Run on Labor Day

in News by Abby Shelton
August 30, 2014 1689

Owensboro Traffic Advisory

in News by Keith Todd
August 28, 2014 1478

Daviess County Sheriff’s Office Activity…

in News by Dennis Beard, SurfKY News

Most Read Stories from Muhlenberg County

August 28, 2014 7559

Police Pursuit Spans Parts of Northern…

in Top Stories by Alex Piper, MCSO
August 29, 2014 3946

Business Spotlight - Magical Memories…

in Top Stories by Charles W. Riley II, SurfKY News
August 28, 2014 3600

Another Greenville Home Invasion Being…

in Top Stories by Wes Miller, GPD
August 28, 2014 2368

Whitfield, Yonts Pay Tribute to Bob and…

in Top Stories by Paul McRee, SurfKY News
August 28, 2014 2272

Stanton Barrett's NASCAR Mustang Gets…

in Top Stories by Charles W. Riley II, SurfKY News

SurfKY News Group, Inc. Central Office & Printing Division
1125 Nebo Rd.  •  Madisonville, KY 42431  •  270.452.2249 (fax)
Main Number: 270.452.2727 (phone)  •  Printing Division Direct Line: 270.821.8600 (phone)

SurfKY Owensboro News Bureau
920 Frederica St. / Suite 210  •  Owensboro, KY 42301  •  270.683-8060 (phone)


Contact a member of our staff: www.surfky.com/contact
Copyright © 2014 SurfKY News Group, Inc.  •  Terms of Use  •  Site Map

social 03social 04social 22social 21social 06